Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

116
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
116
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

123
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
123

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anterior cerebral artery variants and their influence on endovascular outcomes: a propensity score matched analysis from the CRETA registry.

Neuroradiology·2026
Same author

Middle meningeal artery embolization for chronic subdural hematoma: the role of timing and baseline hematoma volume.

Neuroradiology·2026
Same author

CT Quantification of Intraventricular Hemorrhage Volume in Poor-Grade Aneurysmal Subarachnoid Hemorrhage: Impact on Mortality and Long-Term Disability.

Neurocritical care·2026
Same author

Bridging therapy versus mechanical thrombectomy alone in patients with basilar artery occlusion and mild symptoms: a retrospective observational study.

Journal of neurology·2026
Same author

Interaction of Intraprocedural Antiplatelets and Intravenous Thrombolysis in Acute Intracranial Stenting: RESISTANT Registry Subanalysis.

Annals of clinical and translational neurology·2026
Same author

The Revolve Study: A Multicenter Registry Using the Flow Diverter Surpass Evolve® Device for the Endovascular Treatment of Intracranial Aneurysms.

Neurosurgery·2026
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K

In active ulcerative colitis, risankizumab induced and maintained remission.

Alessandro Pedicelli1, Waqqas Afif1

  • 1McGill University, Montreal, Quebec, Canada (A.P., W.A.).

Annals of Internal Medicine
|November 4, 2024
PubMed
Summary
This summary is machine-generated.

Risankizumab effectively treated moderate to severe ulcerative colitis in two clinical trials. Patients achieved clinical remission and endoscopic improvement, showcasing its therapeutic potential.

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

822
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.5K

Related Experiment Videos

Last Updated: Jun 8, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

822
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.5K

Area of Science:

  • Gastroenterology and Hepatology
  • Immunology
  • Clinical Trials

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease with significant unmet needs.
  • Current treatments for UC have limitations in efficacy and safety.
  • Novel therapeutic targets are crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of risankizumab in patients with moderate to severe ulcerative colitis.
  • To assess clinical remission and endoscopic healing with risankizumab treatment.
  • To compare risankizumab's performance against placebo in randomized controlled trials.

Main Methods:

  • Two Phase 3 randomized, double-blind, placebo-controlled trials (INSPIRE and COMMAND) were conducted.
  • Adult patients with moderate to severe active ulcerative colitis were enrolled.
  • Patients received intravenous risankizumab induction followed by subcutaneous maintenance therapy or placebo.

Main Results:

  • Risankizumab demonstrated statistically significant higher rates of clinical remission at week 52 compared to placebo.
  • Endoscopic improvement was significantly greater in the risankizumab groups.
  • Adverse event profiles were comparable between risankizumab and placebo groups, with no new safety concerns identified.

Conclusions:

  • Risankizumab is an effective and safe treatment option for moderate to severe ulcerative colitis.
  • The drug offers a promising new therapeutic avenue for patients with UC.
  • Long-term data will further elucidate the sustained efficacy and safety of risankizumab.